Evaluation of Fitusiran for Bleed Prevention in Patients with Severe Hemophilia A Previously Treated with Emicizumab

The primary objective of this study is to evaluate the efficacy of **fitusiran** in preventing bleeding episodes in individuals with severe **Hemophilia A** who have previously received prophylactic treatment with emicizumab. This is clinically relevant as it aims to provide an alternative therapeutic option that could potentially improve the management of bleeding risks in this patient population.

The clinical trial involves a total of **20 participants** diagnosed with **Hemophilia A**. The study population consists exclusively of male subjects, as female subjects are not included. Participants fall within the age range categories of 3 and 4, indicating a focus on both adolescent and adult males. The selection process for the trial population did not target any vulnerable groups. No specific lifestyle considerations such as diet, physical activity, or habits have been highlighted for this study. The sponsor has not provided detailed information regarding the main objective of the trial or the principal inclusion criteria.

The clinical trial is designed to evaluate the efficacy of **fitusiran** in preventing bleeds in individuals with severe **Hemophilia A** who have previously received preventive treatment with emicizumab. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated recruitment start date is December 29, 2023, with an anticipated end date of December 10, 2027. Participants will be randomly assigned to receive either the investigational drug or a control, with neither the participants nor the investigators aware of the group assignments to maintain the study's double-blind nature.

The trial will include several key visits: an initial screening visit to determine eligibility, regular follow-up visits to monitor safety and efficacy, and an end-of-study visit to assess overall outcomes. The inclusion visit will involve comprehensive screening procedures to ensure participants meet the study's eligibility criteria. Follow-up visits will occur at predetermined intervals to collect data on the primary and secondary endpoints, as well as to monitor any adverse events. The end-of-study visit will provide a final assessment of the participant's health status and the treatment's effectiveness.

Participant involvement is expected to last for the duration of the trial, from the initial screening through to the end-of-study visit. However, certain conditions may lead to early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent, or non-compliance with study protocols. The trial's design and procedures are structured to ensure the collection of robust and reliable data while prioritizing participant safety and adherence to ethical standards.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 29, 2023, with an estimated completion date of December 10, 2027. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger patient population. The trial's design will likely include regular assessments at various timepoints to monitor progress and gather comprehensive data on the treatment's impact. The results will contribute to determining the treatment's potential benefits and inform future clinical and regulatory decisions.